NGENF

NervGen Pharma (QX) Stock Price

1.02
-0.03 (-2.86%)
1.02
Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
NervGen Pharma Corporation (QX) NGENF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.03 -2.86% 1.02 10:22:24
Close Price Low Price High Price Open Price Previous Close
1.01 1.032 1.032 1.05
Bid Price Ask Price Spread News
1.01 1.05 0.04 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
24 15,200 $ 1.0146 $ 15,422 16,699 0.5502 - 2.48989
Last Trade Time Type Quantity Stock Price Currency
10:12:55 100 $ 1.02 USD

NervGen Pharma (QX) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 35.82M 35.11M 23.28M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
12.28k $ - 0.00% - -

more financials information »

NervGen Pharma (QX) News

Real-Time news about NervGen Pharma Corporation (QX) (OTCMarkets): 0 recent articles
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NGENF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.20051.271.011.1217,197-0.18051-15.04%
1 Month1.261.29131.011.1710,914-0.24-19.05%
3 Months1.661.701.011.3317,890-0.64-38.55%
6 Months0.652.20140.55021.4320,3690.3756.92%
1 Year0.99752.48990.55021.5125,5780.02252.26%
3 Years1.18872.48990.55021.4821,563-0.1687-14.19%
5 Years1.18872.48990.55021.4821,563-0.1687-14.19%

NervGen Pharma (QX) Description

NervGen is restoring life's potential by creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. The Company is developing drugs for the treatment of spinal cord injury, multiple sclerosis and Alzheimer's disease. NervGen's platform technology targets protein tyrosine phosphatase sigma ("PTPo"), a neural receptor that impedes nerve repair. Inhibition of the PTPo receptor has been shown to promote regeneration and remyelination of damaged nerves, as well as improvement of nerve function in animal models for various medical conditions.
Your Recent History
USOTC
NGENF
NervGen Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200925 14:41:05